-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NxUwAYPLT+Lecy4TRXl+8Y0qf4Yr4GKi71Y6Th61RtzCh7CyKTdDugJDjHZWyG9f
 y0ARn37TR8PnBXSWjVP3Wg==

<SEC-DOCUMENT>0001181431-07-037182.txt : 20070604
<SEC-HEADER>0001181431-07-037182.hdr.sgml : 20070604
<ACCEPTANCE-DATETIME>20070604080913
ACCESSION NUMBER:		0001181431-07-037182
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20070531
FILED AS OF DATE:		20070604
DATE AS OF CHANGE:		20070604

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			eGENE, INC.
		CENTRAL INDEX KEY:			0001105409
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870645507

	BUSINESS ADDRESS:	
		STREET 1:		5525 SOUTH 900 E
		STREET 2:		SUITE 110
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84117
		BUSINESS PHONE:		949 250 8686

	MAIL ADDRESS:	
		STREET 1:		17841 FITCH
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CENTROID CONSOLIDATED MINES CO
		DATE OF NAME CHANGE:	20000204

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			QIAGEN NV
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-32393
		FILM NUMBER:		07895796

	BUSINESS ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
		BUSINESS PHONE:		31-77-320-8400

	MAIL ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd161189.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2007-05-31</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001105409</issuerCik>
        <issuerName>eGENE, INC.</issuerName>
        <issuerTradingSymbol>EGEI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001015820</rptOwnerCik>
            <rptOwnerName>QIAGEN NV</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O QIAGEN NORTH AMERICAN HOLDINGS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>19300 GERMANTOWN ROAD</rptOwnerStreet2>
            <rptOwnerCity>GERMANTOWN</rptOwnerCity>
            <rptOwnerState>MD</rptOwnerState>
            <rptOwnerZipCode>20874</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2007-05-31</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.31</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>642500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5902205</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Note</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">As of the date hereof, QIAGEN North American Holdings, Inc. (&quot;Holdings&quot;), a wholly-owned subsidiary of QIAGEN N.V., a Dutch public limited liability company (&quot;QIAGEN&quot;), is party to voting agreements dated as of April 12, 2007 (the &quot;Voting Agreements&quot;), with each of the directors and executive officers of eGene, Inc. (&quot;eGene&quot;) and certain other stockholders of eGene, which Voting Agreements were entered into in connection with the Agreement and Plan of Merger, dated as of April 12, 2007 (the &quot;Merger Agreement&quot;), among Holdings, Electra Merger Sub, Inc., a Nevada corporation and a wholly owned subsidiary of Holdings, and eGene. Pursuant to the Voting Agreements, Holdings has been granted a proxy to vote the 5,902,205 shares of eGene common stock that are subject to the Voting Agreements (collectively, the &quot;Shares&quot;) on all matters relating to the merger. Accordingly, QIAGEN may be deemed to beneficially own an aggregate of 5,9
02,205 Shares.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Roland Sackers</signatureName>
        <signatureDate>2007-06-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
